

Aminated (Cyclopropylmethyl)Phosphonates: Synthesis and Anti-Pancreatic Cancer Activity

Abed Al Aziz Al Quntar^{1*}, Ibrahim Abasy², Hasan Dweik¹, Michel Maffei³, Valery M. Dembitsky^{4*}

¹Department of Chemistry and Chemical Technology, Faculty of Science and Technology, Al-Quds University, Jerusalem, Palestine ²Department of Microbiology and Immunology, Al-Quds University, Jerusalem, Palestine

³Institut des Sciences Moleculaires de Marseille (iSm2), Aix-Marseille University, CNRS, Centrale Marseille, Marseille, France ⁴Bio-Geo-Chem Laboratories, Ltd., Aliso Viejo, USA

Email: *abedalaziz@staff.alquds.edu

How to cite this paper: Quntar, A.A.A., Abasy, I., Dweik, H., Maffei, M. and Dembitsky, V.M. (2023) Aminated (Cyclopropylmethyl)Phosphonates: Synthesis and Anti-Pancreatic Cancer Activity. *International Journal of Organic Chemistry*, **13**, 129-136. https://doi.org/10.4236/ijoc.2023.134010

Received: October 22, 2023 Accepted: December 19, 2023 Published: December 22, 2023

Copyright © 2023 by author(s) and Scientific Research Publishing Inc. This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).

http://creativecommons.org/licenses/by/4.0/

Abstract

Buoyed by the extensive research on the wide-range biological activities of aminophosphonates, a novel class of aminated (cyclopropylmethyl)phosphornates compounds was synthesized from diethyl ((1-(3-chloropropyl)cyclopropyl)methyl)phosphonate and various amines in the presence of Hunig's base. Upon biological activity screening these compounds demonstrated encouraging anti-pancreatic cancer properties at low micromolar concentrations.

Keywords

Phosphonates, Aminophosphonates, Pancreatic Cancer, Cancer, Cyclopropylphosphonates

["] 1. Introduction

Organophosphorus compounds, distinct for their (C-P) chemical bond resistant to hydrolytic enzymatic degradation, such as by phospholipase D, are noteworthy natural products [1]-[7]. These compounds prominently feature in phosphonolipids, abundantly found in diverse sources including shellfish, plant seeds, protozoa, and bacteria [1] [2] [3] [8] [9] [10] [11]. Geological evidence has traced the presence of phosphonates on Earth back hundreds of millions of years [12]. However, the role of natural phosphonic compounds in living organisms was only confirmed in the latter half of the twentieth century when 2-aminoethylphosphonic acid was isolated from rumen protozoa by Horiguchii and Kandatsu [13].

The fascination with phosphonate compounds has surged recently due to their broad spectrum of biological activities. Synthesized phosphonates have demon-

strated significant potential, including antiviral and anticancer properties [14] [15] [16] [17]. For instance, organic compounds with phosphonate functional groups serve as antiviral agents and anticancer therapeutics [18], and short peptides with aminophosphonic acids exhibit strong antihypertensive and anti-osteoporotic effects [19]. Phosphonopeptides, where a phosphonic acid or a similar group (phosphine or phosphinic) replaces a carboxyl group at the C-terminus or in the peptidyl side chain, or where a phosphonamidate or phosphinic acid mimics a peptide bond, act as inhibitors of crucial enzymes linked to various diseases. These compounds have shown promising physiological activities and have potential medical applications, including as anticancer agents, inhibitors of aminopeptidases, and as blockers of protein tyrosine phosphatase [20].

Pancreatic cancer, recognized as one of the most aggressive forms of cancer, is responsible for about 7% of all cancer-related deaths. Often diagnosed in advanced stages, it has a high mortality rate. Early detection through imaging techniques, along with the identification of genetic mutations in KRAS, TP53, CDKN2A, SMAD4, and BRCA genes, can enhance treatability. Despite this, treating pancreatic cancer remains challenging. While surgery and radiation therapy are employed, chemotherapy remains the predominant treatment modality [21] [22].

This work is an extension of our ongoing research on organophosphonate compounds and is devoted to the synthesis of aminated (cyclopropylmethyl)pho-sphonates, which demonstrated anti-pancreatic cancer activity.

2. Results and Discussion

Previously, we reported the synthesis of (cyclopropylmethyl)phosphonates **2** using 1-alkynylphosphonates **1** with the reagent system $Cp_2ZrCl_2/2EtMgBr/2AlCl_3$ (Equation 1) [23].

$$R \xrightarrow{\bigcup_{i=1}^{U} OEt}_{OEt} \underbrace{(1) Cp_2 ZrCl_2 / 2 EtMgBr}_{(2) 2 AICl_3, -30^{\circ}C} \xrightarrow{R}_{P(O)(OEt)_2}^{H} eq.1$$

Equation 1. Synthesis of (cyclopropylmethyl)phosphonates 2.

Inspired by the wide range of biological applications of aminophosphonates, our team sought to enhance the biological activity of our (cyclopropylmethyl)phosphonates compound 2 by introducing an amino group. We anticipated that positioning the amine group in close proximity to both the cyclopropyl ring and the phosphonate moiety might enhance the biological activity of these molecules.

To achieve this, we aminated a representative class of (cyclopropylmethyl)phosphonates using Hünig's base [24]. Our starting material, diethyl ((1-(3-chloropropyl)cyclopropyl)methyl)phosphonate **5**, was synthesized from diethyl (5chloropent-1-yn-1-yl)phosphonate **3** via a five-membered ring zirconacycle intermediate **4**, as depicted in **Scheme 1** [23]. Subsequently, reacting 1.2 equivalents of an amine with two equivalents of Hünig's base diisopropylethylamine (DIPEA) in a solvent-free process yielded the target aminated products **6**a-c with isolated yields ranging from (68% - 73%).

These novel aminated cyclopropyl-methylphosphonate compounds (Figure 1) were separated from the reaction mixture on silica gel column (93% ethyl acetate:



Scheme 1. Synthesis of aminated (cyclopropylmethyl)phosphonates 6.



Figure 1. Pancreatic activity of the tested compounds (2a, 5, 6a-c).

7% methanol) and were analyzed by GC/MS, NMR, and elemental analysis.

Furthermore, their biological activity was explored as anti pancreatic cancer cells system. Luckily, they were found to possess potent suppression of the cancer cells in the cell line as shown in **Figure 1**.

Diethyl ((1-propylcyclopropyl)methyl)phosphonate 2a and the chlorinated counterpart 5 were evaluated to ascertain the impact of the amine group on anticancer activity. Intriguingly, the data revealed that amine integration into the cyclopropyl framework notably boosted activity against pancreatic cancer cells. As depicted in Figure 1, while the aminated derivatives 6a and 6b displayed moderate efficacy in inhibiting pancreatic cell proliferation, diethyl (1-(4-(ben-zylamino)butyl)cyclopropyl)methylphosphonate 6c emerged as the most potent inhibitor, exhibiting significant cell suppression at low micromolar concentrations with an IC50 of approximately $45 \mu M$.

In summary, the newly synthesized aminated (cyclopropylmethyl)phosphornates demonstrated promising anti-pancreatic cancer activity, particularly when a benzylamine group was incorporated into the cyclopropylmethylphosphonate framework. Motivated by these in vitro findings, we plan to extend our research to in vivo studies and to evaluate the efficacy of these compounds against other types of cancer cells.

3. Experimental

The ¹H, ¹³C, and ³¹P NMR spectra were recorded from solutions in $CDCl_3$ on a Varian Mercury 300 spectrometer at 300, 75.5, and 121.4 MHz, respectively; the chemical shifts were measured relative to TMS (¹H, ¹³C) and H₃PO₄.

Pancreatic cell proliferation assay: Pancreatic cancer cell line (PANC-1) from (Sigma-Aldrich) has been used to study the effect of the synthesised drug combinations. At regular basis cells were cultured in 25 ml culture flasks containing DMEM media (Sigma-Aldrich) plus (2 mM Glutamine, 10% Foetal Bovine Serum (FBS), and 1% pencillin/streptomycin solution) and kept at 37°C CO_2 incubator. Cells were counted and adjusted to a concentration of ~2 \times 10^{5} /ml in complete culture medium, then (aliquot of 100 µl of cells) were seeded in 96-well sterial culture plate. This was followed by the addition of 50 μ l of freshly prepared drug dilutions (from 10 mM to 100 mM) to the seeded pancreatic cells, drug free media was added as a control. Diluted drugs were added to the seeded pancreatic cells in triplicate, then plates were incubated for 24 hours at 5% CO₂ and 37°C. Cell viability was measured using Almar Blue (Bio-Rad cat No. BUF012A), for this purpose Almar blue (10% of final volume, 25 µl/well) was added to each well, followed by incubation at 5% CO₂ and 37°C for 4 hours. Fluorescence was measured at 535/590nm excitation/emission wavelength on plate reader. Cell viability percentages were calculated relative to untreated control.

General procedure for the synthesis of Diethyl (1-(3-chloropropyl)-cyc-lopropyl)methylphosphonate 5: To 0.306 g (1.05 mmol) of zirconocene dichloride dissolved in 7 ml of dry THF at -78°C was added 1.05 ml of 2 M EtMgBr

(2.1 mmol) dropwise in a 25 ml round-bottom flask. After stirring for 5 min at -78°C, 1 mmol (0.22 g) of 6-chloro-diethyl hex-1-ynylphosphonate was added. The reaction was gradually warmed to 25°C and stirred for 2 hr. The reaction was cooled to -30°C and maintained at -30°C - 40°C while 2 equiv. of AlCl₃ were added. The reaction was stirred for 1 hr at -30°C and was worked up with dilute HCl. The product was extracted with diethyl ether (2 × 15 ml) and was separated on silica gel column (70% petroleum ether: 30% ethyl acetate).

¹H NMR (300 MHz): δ 0.30 (m, 2H), 0.47 (m, 2H), 1.15 (t, 2H, $J_{HH} = 7.5$ Hz), 1.30 (dt, 6H, $J_{HH} = 6.9$, ${}^{4}J_{PH} = 0.2$ Hz), 1.36 (m, 2H), 1.71 (d, 2H, ${}^{2}J_{PH} = 18.0$ Hz), 3.52 (t, 2H, $J_{HH} = 7.5$ Hz), 3.98 - 4.15 (m, 4H). ³¹P NMR (121.4 MHz): δ 31.92. ¹³C NMR (75.5 MHz): δ 12.7, 12.8, 15.0 (d, ${}^{2}J_{PC} = 4.3$ Hz), 16.4 (d, ${}^{3}J_{PC} = 6.3$ Hz), 17.9, 24.7, 32.4 (d, ${}^{1}J_{PC} = 140.1$ Hz), 40.2, 41.0, 47.4, 61.3 (d, ${}^{2}J_{PC} = 6.6$ Hz). MS m/z: 270 (0.3), 268 (1.0), 233 (70.6), 231 (66.7), 219 (28.4), 205 (44.1), 177 (46.0), 163 (46.0), 149 (63.7), 148 (40.2), 125 (38.2), 111 (100), 99 (92.2), 97 (92.2), 81 (91.8), 67 (60.8), 41 (68.6), 29 (53.9). Anal. Calcd for C₁₁H₂₂ClO₃P: C, 49.17; H, 8.25; Cl, 13.19; P, 11.53. Found: C, 49.08; H, 8.31; Cl, 13.29; P, 11.43.

Synthesis of diethyl ((1-(3-(pentylamino)propyl)cyclopropyl)methyl) phosphonate 6a:



To 0.5 mmol of the chlorinated cyclopropyl product **5**, 1.2 eqiv. of amyl amine and 2 eqiv. of Hunig's base were added and the mixture was heated for 48 hours at 70°C in a hermetically sealed 5 mL glass vial. Then the aminated cyclopropyl product was separated on silica gel column (93% ethyl acetate: 10 % methanol) to give the oily products in 73% yield.

¹H NMR (300 MHz): δ 0.26 (m, 2H), 0.32 (m, 2H), 0.90 (t, 3H, $J_{\text{HH}} = 6.3$), 1.20 - 1.45 (overlap, 10H), 1.30 (t, 6H, $J_{\text{HH}} = 7.2$). 1.70 (d, 2H, ² $J_{\text{PH}} = 16.2$ Hz), 2.80 (broad m, 2H), 2.90 (t, 2H, $J_{\text{HH}} = 6.3$), 3.84 (q, 4H, $J_{\text{HH}} = 7.2$). ³¹P NMR (121.4 MHz): δ 23.0. ¹³C NMR (75.5 MHz): δ 13.0, 13.2, 13.7, 16.7 (d, ² $J_{\text{PC}} = 6.6$ Hz), 22.6, 24.1, 24.5, 25.4, 27.3, 28.7, 33.9 (d, ¹ $J_{\text{PC}} = 134.5$ Hz), 35.8, 37.9, 39.6, 47.1, 59.6, (d, ² $J_{\text{PC}} = 5.1$ Hz). MS *m*/*z*: 319 (5.8), 304 (18.8), 290 (23.2), 274 (40.3), 262 (45.8), 227 (65.2), 182 (100), 137 (29.4), 97 (43.2), 57 (87.3). Anal. Calcd for C₁₆H₃₄NO₃P: C, 60.16; H, 10.73; N, 4.39; P, 9.70 Found C, 59.97; H, 10.62; N, 4.50; P, 9.79.

Synthesis of diethyl((1-(3-(isopropylamino)propyl)cyclopropyl)methyl) phosphonate 6b:



Identical procedure to the synthesis of **6**a except adding *i*propyl amine and the yield was 68%.

¹H NMR (300 MHz): $\delta 0.29$ (m, 2H), 0.35 (m, 2H), 1.20 (d, 6H, $J_{\rm HH} = 7.2$), 1.25 - 1.40 (overlap, 10H), 1.69 (d, 2H, ${}^{2}J_{\rm PH} = 16.2$ Hz), 2.62 (t, 2H, $J_{\rm HH} = 6.3$), 2.87 (m, 1H), 3.84 (q, 4H, $J_{\rm HH} = 7.2$). ³¹P NMR (121.4 MHz): δ 23.48. ¹³C NMR (75.5 MHz): δ 13.0, 13.6, 13.9, 16.8 (d, ${}^{2}J_{\rm PC} = 6.6$ Hz), 18.8, 20.3, 22.2, 27.5, 28.7, 28.9, 34.2 (d, ${}^{1}J_{\rm PC} = 177.9$ Hz), 41.2, 45.8, 60.0 (d, ${}^{2}J_{\rm PC} = 5.1$ Hz). MS *m*/*z*: 291 (7.8), 276 (12.2), 261 (18.8), 248 (55.7), 233 (60.4), 220 (49.8), 205 (23.2), 154 (61.8), 111 (78.1), 96 (20.3), 81 (60.5), 58 (53.2) 43 (100). Anal. Calcd for C₁₄H₃₀NO₃P: C, 57.71; H, 10.38; N, 4.81; P, 10.63 Found: C, 57.65; H, 10.27; N, 4.94; P, 10.77.

Synthesis of diethyl (1-(4-(benzylamino)butyl)cyclopropyl) methylphosphonate 6c:



Identical procedure to 6a except adding benzyl amine and the yield was 70%.

¹H NMR (300 MHz): δ 0.26 (m, 2H), 0.33 (m, 2H), 1.22 (t, 2H, $J_{HH} = 6.9$), 1.28 - 1.38 (overlap, 8H), 1.59 (d, 2H, ² $J_{PH} = 16.8$ Hz), 3.48 (t, 2H, $J_{HH} = 7.5$ Hz), 3.71 (s, 2H), 3.95 (q, 4H, $J_{HH} = 6.9$), 7.28-2.67 (overlap, 5H). ³¹P NMR (121.4 MHz): δ 22.75. ¹³C NMR (75.5 MHz): δ 13.0, 13.2, 13.4, 17.0 (d, ² $J_{PC} = 4.3$ Hz), 21.8, 24.1, 24.5, 33.9 (d, ¹ $J_{PC} = 132.7$ Hz), 35.1, 43.6, 50.4, 59.8 (d, ² $J_{PC} = 6.6$ Hz), 127.9, 128.4, 128.7, 132.4, 131.7. MS *m*/*z*: 339 (8.7), 324 (17.2), 294 (40.1), 242 (51.2), 228 (74.0), 182 (55.8), 91 (100), 77 (78.5), 43 (47.2). Anal. Calcd for C₁₈H₃₀NO₃P: C, 63.70; H, 8.91; N, 4.13; P, 9.13 Found: C, 63.58; H, 8.83; N, 4.24; P, 9.26.

2a: Diethyl ((1-propylcyclopropyl)methyl)phosphonate [23].



Conflicts of Interest

The authors declare no conflicts of interest regarding the publication of this paper.

References

- Moschidis, M.C. (1984) Phosphonolipids. *Progress in Lipid Research*, 23, 223-246. <u>https://doi.org/10.1016/0163-7827(84)90012-2</u>
- [2] Hori, T. and Nozawa, Y. (1982) Phosphonolipids. New Comprehensive Biochemistry, 4, 95-128. <u>https://doi.org/10.1016/S0167-7306(08)60007-1</u>
- [3] Mukhamedova, K.S. and Glushenkova, A.I. (2000) Natural Phosphonolipids. *Chemistry of Natural Compounds*, 36, 329-341. https://doi.org/10.1023/A:1002804409503
- [4] Selvy, P.E., Lavieri, R.R., Lindsley, C.W. and Brown, H.A. (2011) Phospholipase, D:

Enzymology, Functionality, and Chemical Modulation. *Chemical Reviews*, **111**, 6064-6119. <u>https://doi.org/10.1021/cr200296t</u>

- [5] Exton, J.H. (1997) Phospholipase D: Enzymology, Mechanisms of Regulation, and Function. *Physiological Reviews*, **77**, 303-320. https://doi.org/10.1152/physrev.1997.77.2.303
- [6] Jenkins, G.M. and Frohman, M.A. (2005) Phospholipase D: A Lipid Centric Review. *Cellular and Molecular Life Sciences CMLS*, 62, 2305-2316. <u>https://doi.org/10.1007/s00018-005-5195-z</u>
- [7] Exton, J.H. (2002) Phospholipase D—Structure, Regulation and Function. In: Exton, J.H., Ed., *Reviews of Physiology, Biochemistry and Pharmacology*, Springer, Berlin, 1-94. <u>https://doi.org/10.1007/BFb0116585</u>
- [8] Horsman, G.P. and Zechel, D.L. (2017) Phosphonate Biochemistry. *Chemical Reviews*, 117, 5704-5783. <u>https://doi.org/10.1021/acs.chemrev.6b00536</u>
- [9] Hanuš, L.O., Levitsky, D.O., Shkrob, I. and Dembitsky, V.M. (2009) Plasmalogens, Fatty Acids and Alkyl Glyceryl Ethers of Marine and Freshwater Clams and Mussels. *Food Chemistry*, **116**, 491-498. <u>https://doi.org/10.1016/j.foodchem.2009.03.004</u>
- [10] Levitsky, D.O., Goldshlag, P. and Dembitsky, V.M. (2015) Profiling of Bioactive Lipids of the Wild Edible Land Snails of the Genus Helix. *SDRP Journal of Food Science & Technology*, 1, 1-10.
- [11] Kostetsky, E.Y. and Velansky, P.V. (2009) Phospholipids of Sea Worms, Mollusks, and Arthropods. *Russian Journal of Marine Biology*, **35**, 187-199. https://doi.org/10.1134/S1063074009030018
- [12] Quinn, J.P., Kulakova, A.N., Cooley, N.A. and McGrath, J.W. (2007) New Ways to Break an Old Bond: The Bacterial Carbon-Phosphorus Hydrolases and Their Role in Biogeochemical Phosphorus Cycling. Environmental Microbiology, 9, 2392-2400. https://doi.org/10.1111/j.1462-2920.2007.01397.x
- [13] Horiguchi, M. and Kandatstu, M. (1959) Isolation of 2-Aminoethane Phosphonic Acid from Rumen Protozoa. *Nature*, 184, 901-902. https://doi.org/10.1038/184901b0
- [14] Al Quntar, A.A., Srebnik, M., Terent'ev, A.O. and Dembitsky, V.M. (2014) Cyclobutyl- and Cyclobutenylphosphonates: Synthesis, Transformations and Biological Activities. *Mini-Reviews in Organic Chemistry*, 11, 445-461. <u>https://doi.org/10.2174/1570193X1104140926170132</u>
- [15] Dembitsky, V.M., Al Quntar, A.A, Haj-Yehiaa, A. and Srebnik, M. (2005) Recent Synthesis and Transformation of Vinylphosphonates. *Mini-Reviews in Organic Chemistry*, 2, 91-109. <u>https://doi.org/10.2174/1570193052774090</u>
- [16] Dembitsky, V.M., Gloriozova, T.A. and Savidov, N. (2018) Steroid Phosphate Esters and Phosphonosteroids and Their Biological Activities. *Applied Microbiology and Biotechnology*, **102**, 7679-7692. <u>https://doi.org/10.1007/s00253-018-9206-z</u>
- [17] Al Quntar, A.A., Dembitsky, V.M. and Srebnik, M. (2008) *a*-, β-, γ- and ω-Cyclopropylphosphonates. Preparation and Biological Activity. *Organic Preparations and Procedures* International, **40**, 505-542. <u>https://doi.org/10.1080/00304940809458117</u>
- [18] Krise, J.P. and Stella, V.J. (1996) Prodrugs of Phosphates, Phosphonates, and Phosphinates. Advanced Drug Delivery Reviews, 19, 287-310. https://doi.org/10.1016/0169-409X(95)00111-J
- [19] Lejczak, B. and Kafarski, P. (2009) Biological Activity of Aminophosphonic Acids and Their Short Peptides. In: Bansal, R., ed., *Phosphorous Heterocycles I. Topics in Heterocyclic Chemistry*, Springer, Berlin, 31-63.

https://doi.org/10.1007/7081_2008_14

- [20] Kafarski, P. (2020) Phosphonopeptides Containing Free Phosphonic Groups: Recent Advances. *RSC Advances*, **10**, 25898-25910. <u>https://doi.org/10.1039/D0RA04655H</u>
- [21] Bailey, P., *et al.* (2016) Genomic Analyses Identify Molecular Subtypes of Pancreatic Cancer. *Nature*, **531**, 47-52.
- [22] Ghaneh, P., et al. (2019) Pancreatic Cancer. The Lancet, 393, 1697-1710.
- [23] Sinelinkove, Y., Al Quntar, A.A., Rubnishtien, A. and Srebnik, M. (2009) Direct Formation of Cyclobutenylphosphonates from 1-Lkynylphosphonates and Cp₂ZrCl₂/2Et-MgCl/2CuCl. *Tetrahedron Letters*, **50**, 867-869. https://doi.org/10.1016/j.tetlet.2008.11.108
- [24] Taywadea, A. and Berad, B. (2019) Hunig's Base a Facile and Green Alternative for C-N Bond Formation Reactions. *Indian Journal of Chemistry—Section B*, 58B, 935-943.